Join BJS Academy
BJS Academy>Randomized clinical ...>Perioperative camrel...
Normal View Dyslexic View

Perioperative camrelizumab plus rivoceranib versus surgery alone in patients with resectable hepatocellular carcinoma at intermediate or high risk of recurrence (CARES-009): a randomised phase 2/3 trial

9 January 2026
HPB
BJSA
BJS Academy
0000-0000
BJS Foundation Limited
London, UK
BJS-2026-0006
Randomized Clinical Trials
HPB
Perioperative camrelizumab plus rivoceranib versus surgery alone in patients with resectable hepatocellular carcinoma at intermediate or high risk of recurrence (CARES-009): a randomised phase 2/3 trial
09012026
Wang Z, Fan J, Zhou S, Sun Y, Liang F, Ji Y et al.
Lancet 2025; 406: 2089-2099.
The addition of perioperative chemotherapy significantly improved event-free survival after surgery from a median of 19.4 to 42.1 months in this study that included 294 patients.
Comment: Important study in operable patients.
cover image
Published on: 9 January 2026
Article ID: BJS-2026-0006

Related articles

Temporary portocaval shunt provides superior intraoperative hemodynamics and reduces blood loss and duration of surgery in live donor liver transplantation. A randomized controlled trial.

Kumar M, Patil NS, Mohapatra N, Sindwani G, Dhingra U, Yadav A et al.
Ann Surg 2024; 279: 932-944.

16 August 2024

Upfront endoscopic necrosectomy or step-up endoscopic approach for infected necrotising pancreatitis (DESTIN): a single-blinded, multicentre, randomised trial.

Bang JY, Lakhtakia S, Thakkar S, Buxbaum JL, Waxman I, Sutton B et al, on behalf of the United States Pancreatic Disease Study Group.

16 August 2024

Neoadjuvant FOLFIRINOX versus upfront surgery for resectable pancreatic head cancer (NORPACT-1): a multicentre, randomised, phase 2 trial.

Labori KJ, Bratlie SO, Andersson B, Angelsen J-H, Biorserud C, Bjornsson B et al, for the Nordic Pancreatic Cancer Trial-1 study group.

30 August 2024
Home
  • Normal view
  • Dyslexic view
Info
Copied!